{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T23:34:33Z","timestamp":1648683273168},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ijrobp.2015.10.005","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T15:18:54Z","timestamp":1449760734000},"page":"211","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Reply to Brown et al"],"prefix":"10.1016","volume":"94","author":[{"given":"David G.","family":"Brachman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.10.005_bib1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ijrobp.2014.12.050","article-title":"Phase 1\/2 trials of temozolomide, motexafin gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: Final results of RTOG 0513","volume":"91","author":"Brachman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijrobp.2015.08.047","article-title":"In regard to Brachman et al","volume":"94","author":"Brown","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib4","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1074\/jbc.M511373200","article-title":"Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase","volume":"281","author":"Hashemy","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib5","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1158\/0008-5472.CAN-05-2754","article-title":"Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines","volume":"65","author":"Lecane","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib6","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1158\/0008-5472.CAN-04-4099","article-title":"Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines","volume":"65","author":"Magda","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/1078-0432.CCR-05-0743","article-title":"Motexafin- gadolinium taken up in-vitro by at least 90% of glioblastoma cell nuclei","volume":"12","author":"De Stasio","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib8","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2003.12.122","article-title":"Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases","volume":"21","author":"Mehta","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ijrobp.2007.04.017","article-title":"Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme","volume":"69","author":"Ford","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.005_bib10","first-page":"86","article-title":"Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent","volume":"60","author":"Bernhard","year":"2000","journal-title":"Cancer Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615265704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615265704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:20:52Z","timestamp":1537143652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615265704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0360301615265704"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.005","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Reply to Brown et al","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.08.047","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}